Proprietary Subcutaneous Delivery
System and Drug Formulations

Changing the Paradigm of Heart Failure and Infectious Diseases

Administer Parenteral Therapies Outside the Hospital Without the Need for IV Catheters

Transforming Patient Care and Reducing Health Costs Through Innovative Subcutaneous Delivery.

Heart Failure

Subcutaneous administration of furosemide.

Infectious Disease

Subcutaneous delivery of antibiotics.

Why scPharmaceuticals

Changing the Heart Failure Treatment Paradigm with the sc2Wear™ Infusor

scPharmaceuticals - working to enable better care for less through the subcutaneous administration of proven pharmaceuticals.

Learn More

News

Go to News & Events
4/26/17

John Tucker Appointed as Chief Executive Officer of scPharmaceuticals

FOR IMMEDIATE RELEASE: LEXINGTON, MA., —scPharmaceuticals, Inc., a privately held biopharmaceutical company transforming patient care and healthcare costs through innovative subcutaneous drug delivery, today announced the appointment of John Tucker as president and chief executive officer, effective immediately.

1/24/17

scPharmaceuticals Announces Start of SUBQ-HF NHLBI Study with Its Subcutaneous Furosemide Product

FOR IMMEDIATE RELEASE: LEXINGTON, MA., —scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the start of the first phase of a study conducted by the Heart Failure Clinical Research Network (HFN).

1/4/17

scPharmaceuticals Announces Closing of $45.6 Million in Series B Financing

FOR IMMEDIATE RELEASE: LEXINGTON, MA. — scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery announced today that it has closed a $45.6 million Series B investment round.